Ani Pharmaceuticals (ANIP) Enterprise Value (2010 - 2026)

Ani Pharmaceuticals has disclosed Enterprise Value across 17 years of filings, most recently posting -$311.2 million for Q1 2026.

• Enterprise Value for Q1 2026 came in at -$311.2 million, down 107.7% year-over-year; the trailing twelve-month figure through Mar 2026 was -$311.2 million (down 107.7% YoY), and the FY2025 annual result was -$285.6 million, down 97.12% from the prior year.
• Enterprise Value came in at -$311.2 million for Q1 2026 at Ani Pharmaceuticals, down from -$285.6 million in the prior quarter.
• In the past five years, Enterprise Value ranged from a high of -$53.2 million in Q4 2022 to a low of -$311.2 million in Q1 2026.
• The 5-year median for Enterprise Value is -$161.7 million (2023), against an average of -$170.2 million.
• Across the five-year window, Enterprise Value jumped 49.45% in 2022 and plunged 315.38% in 2023, its largest moves.
• Ani Pharmaceuticals' Enterprise Value stood at -$53.2 million in 2022, then slumped by 315.38% to -$221.1 million in 2023, then jumped by 34.47% to -$144.9 million in 2024, then plunged by 97.12% to -$285.6 million in 2025, then dropped by 8.96% to -$311.2 million in 2026.
• The last three Enterprise Value figures came in at -$311.2 million (Q1 2026), -$285.6 million (Q4 2025), and -$262.6 million (Q3 2025), per Business Quant data.